Clinical trials
Phase 3 Multiple Sclerosis trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
65 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 6 |
| 2007 | 5 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 6 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 41 |
| Active, not recruiting | 10 |
| Terminated | 5 |
| Unknown status | 5 |
| Recruiting | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biogen | 8 |
| Novartis Pharmaceuticals | 7 |
| Sanofi | 7 |
| Genzyme, a Sanofi Company | 5 |
| Hoffmann-La Roche | 5 |
| Rennes University Hospital | 4 |
| Actelion | 3 |
| Centre Hospitalier Universitaire de Nice | 3 |
| Novartis | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 65 |
| Multiple Sclerosis, Relapsing-Remitting | 16 |
| Recurrence | 11 |
| Multiple Sclerosis, Chronic Progressive | 6 |
| Urinary Bladder, Neurogenic | 2 |
| Fatigue | 1 |
| Immune System Diseases | 1 |
| Neoplasm Metastasis | 1 |
| Optic Neuritis | 1 |
| Thinness | 1 |
Trials
Showing 1 to 25 of 65. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.